Antiaging Quantum Living Inc (AAQL)

[maverick_1]

Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN)
March 30, 2015
by Zacks Equity Research Published on March 30, 2015
http://www.zacks.com/stock/news/169240/falling-earnings-estimates-signal-weakness-ahead-for-achillion-pharmaceuticals-achn

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Achillion Pharmaceuticals, Inc. (ACHN - Snapshot Report), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ACHN.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 4 estimates moving down in the past 30 days, compared with no upward revision. This trend has caused the consensus estimate to trend lower, going from a loss of 85 cents a share a month ago to its current level of a loss of 97 cents.

Also, for the current quarter, Achillion Pharmaceuticals has seen 2 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to a loss of 22 cents a share from a loss of 19 cents over the past 30 days.

The stock also has seen some pretty dismal trading lately, as the share price has dropped 18.7% in the past month.

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Biomedicine sector, you may instead a better-ranked stock Acorda Therapeutics, Inc. (ACOR - Analyst Report) with a Zacks Rank #1 (Strong Buy).